Abstract Details
|
Danielle M. Andrade, MD
(University of Toronto)
PRESENTER |
The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. The institution of Dr. Andrade has received research support from Epilepsy Canada. The institution of Dr. Andrade has received research support from SynGAP Research Fund. Dr. Andrade has received publishing royalties from a publication relating to health care. Dr. Andrade has a non-compensated relationship as a Former Chair of task force on Transition with International League Against Epilepsy that is relevant to AAN interests or activities. Dr. Andrade has a non-compensated relationship as a President with Canadian League Against Epilepsy that is relevant to AAN interests or activities. |
| No disclosure on file | |
| Julie Turnbull | No disclosure on file |
| Christine Klein, MD (University of Luebeck) | Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Centogene and Retromer Therapeutics. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Mov Disord, Ann Neurol, Science Adv. The institution of Dr. Klein has received research support from Centogene. Dr. Klein has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| No disclosure on file | |
| Berge A. Minassian, MD (Univeristy of Texas Southwestern Medical Center) | Dr. Minassian has nothing to disclose. |
| Richard J. Barohn, MD, FAAN (University of Missouri) | Dr. Barohn has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for NuFactor. The institution of Dr. Barohn has received research support from FDA OPD R01. Dr. Barohn has received intellectual property interests from a discovery or technology relating to health care. |